MorphoSys AG — AGM Information 2003

May 19, 2003

News Details

Corporate | 19 May 2003 08:35

MorphoSys AG english

MorphoSys Announces Re-election of Supervisory Board Members Corporate-news announcement sent by DGAP. The sender is solely responsible for the contents of this announcement. ——————————————————————————– MorphoSys AG (Frankfurt Stock Exchange: MOR; Prime Standard Segment) announced today that at the company’s annual shareholder meeting on Friday, May 16, 2003, the Company’s shareholders confirmed the reappointment of Prof. Dr. Jürgen Drews and Prof. Dr. Andreas Plückthun to MorphoSys’ Supervisory Board. Prof. Dr. Jürgen Drews, Managing Director of the Bear Stearns Health Innoventure Fund, has been a member of the MorphoSys Supervisory Board since 1997, and also holds the position of Vice Chairman. Prof. Dr. Andreas Plückthun, Professor for Biochemistry at the University of Zurich, Switzerland, is a cofounder of MorphoSys. In addition to the confirmation of the appointment of Prof. Dr. Jürgen Drews and Prof. Dr. Andreas Plückthun to the Supervisory Board, all other management proposals of the shareholder assembly agenda were passed at the meeting, which took place in Munich. “We are very pleased that Prof. Dr. Jürgen Drews and Prof. Dr. Andreas Plückthun are reappointed to our board,” commented Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG. “We look forward to continue working with them and I am very grateful for their invaluable input.” About MorphoSys: MorphoSys develops and applies innovative technologies for the production of synthetic antibodies, which accelerate drug discovery and target characterization. Founded in 1992, the Company’s proprietary Human Combinatorial Antibody Library (HuCALâ) technology is used by researchers worldwide for human antibody generation. The Company currently has licensing and research collaborations with Bayer (Berkeley, California/USA), Biogen Inc. (Cambridge, Massachusetts/USA), Boehringer Ingelheim (Ingelheim, Germany), Bristol-Myers Squibb (Wilmington, Delaware/USA), Centocor Inc. (Malvern, Pennsylvania/USA), California/USA), GPC Biotech AG (Munich/Germany), Hoffmann-La Roche AG (Basel/Switzerland), ImmunoGen Inc. (Cambridge, Massachusetts/USA), Oridis Biomed GmbH (Graz/Austria), ProChon Biotech Ltd. (Rehovot/Israel), Schering AG (Berlin/Germany) and Xoma Ltd. (Berkeley, California/USA). For further information please visit the corporate website at: http://www.morphosys.com/. Contact: Dr. Claudia Gutjahr-Löser, Corporate Communications, MorphoSys AG, Tel. +49/89/89927-122 end of message, (c)DGAP 19.05.2003 ——————————————————————————– WKN: 663200; ISIN: DE0006632003; Index: Nemax 50 Listed: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin- Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart 190835 Mai 03